Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd + Rilvegostomig or Rilvegostomig vs Pembrolizumab in 1L Advanced Non-squamous NSCLC
NCT06357533Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan and rilvegostomig in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival in TROP2 biomarker positive participants at 4 years and Overall Survival in TROP2 biomarker positive participants at 6 years. Started Apr 2024; status: recruiting.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06357533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06357533.